Conny Börje Bogentoft
Directeur/Membre du Conseil chez Galenica AB
Profil
Conny Börje Bogentoft is currently a Director at Galenica AB since 2008.
Prior to this, he served as the Chief Executive Officer at Karolinska Development AB (Private Equity) from 2003 to 2010.
He also held director positions at various firms including Promore Pharma AB, Omnio Healer AB, PharmaSurgics In Sweden AB, Umecrine AB, and Lipidor AB.
Postes actifs de Conny Börje Bogentoft
| Sociétés | Poste | Début |
|---|---|---|
Galenica AB
 Galenica AB Pharmaceuticals: MajorHealth Technology Galenica AB develops and manufactures pharmaceutical drugs. It offers service to partners for the development of oral, dermal, nasal, rectal, pulmonary and parenteral formulations of small molecules to peptides/proteins and biologics. The company was founded in 1999 and is headquartered in Malmo, Sweden. | Directeur/Membre du Conseil | 01/01/2008 |
Anciens postes connus de Conny Börje Bogentoft
| Sociétés | Poste | Fin |
|---|---|---|
Omnio Healer AB
 Omnio Healer AB Pharmaceuticals: MajorHealth Technology Omnio Healer AB is a company developing novel drug candidates based on a series of conceptual breakthroughs in inflammation research. This new, pro-inflammatory approach opens up completely new therapeutic strategies for wound healing and anti-infection. The company's lead drug candidate, aimed primarily at otological indications, has achieved promising preclinical results and will enter a clinical development program in late 2010. Since its foundation in 2006 Omnio Healer has assembled a management and development team. This includes scientists within the field, experienced product development professionals and active investors led by Karolinska Development AB, providing access to a network of biotechnology development resources. The company is based in Umeå, Sweden. | Directeur/Membre du Conseil | 19/01/2012 |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | President | 23/08/2010 |
Promore Pharma AB
 Promore Pharma AB BiotechnologyHealth Technology Promore Pharma AB is a biopharmaceutical company, which engages in the development of therapeutic peptides for the bioactive wound care market. The company was founded by Mona Ståhle and Johan Heilborn on January 29, 2003 and is headquartered in Solna, Sweden. | Directeur/Membre du Conseil | - |
Umecrine AB
 Umecrine AB BiotechnologyHealth Technology Umecrine AB provides pharmaceuticals against mental and physical symptoms. It develops antagonists to reduce symptoms and conditions caused by endogenous sex and stress hormones on the brain. The company was founded by Carl Torbjörn Bäckström in 2000 and is headquartered in Umea, Sweden. | Directeur/Membre du Conseil | - |
| LIPIDOR AB | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| LIPIDOR AB | Commercial Services |
| Entreprise privées | 6 |
|---|---|
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Finance |
Promore Pharma AB
Promore Pharma AB BiotechnologyHealth Technology Promore Pharma AB is a biopharmaceutical company, which engages in the development of therapeutic peptides for the bioactive wound care market. The company was founded by Mona Ståhle and Johan Heilborn on January 29, 2003 and is headquartered in Solna, Sweden. | Health Technology |
Omnio Healer AB
Omnio Healer AB Pharmaceuticals: MajorHealth Technology Omnio Healer AB is a company developing novel drug candidates based on a series of conceptual breakthroughs in inflammation research. This new, pro-inflammatory approach opens up completely new therapeutic strategies for wound healing and anti-infection. The company's lead drug candidate, aimed primarily at otological indications, has achieved promising preclinical results and will enter a clinical development program in late 2010. Since its foundation in 2006 Omnio Healer has assembled a management and development team. This includes scientists within the field, experienced product development professionals and active investors led by Karolinska Development AB, providing access to a network of biotechnology development resources. The company is based in Umeå, Sweden. | Health Technology |
PharmaSurgics In Sweden AB
 PharmaSurgics In Sweden AB Pharmaceuticals: MajorHealth Technology PharmaSurgics is a clinical stage biotech company developing novel treatments for the prevention of harmful scarring (adhesions) after surgery. Post-surgical adhesions develop in millions of patients every year and are a source of great patient suffering and enormous healthcare expenditures. The company was founded in 2005 after extensive research done by Dr Inger Mattsby-Baltzer, PhD and Professor Kjell Olmarker MD, PhD at the Sahlgrenska Academy. PharmaSurgics is based in Göteborg, Sweden, where comprehensive in vitro and in vivo facilities have been established. | Health Technology |
Umecrine AB
Umecrine AB BiotechnologyHealth Technology Umecrine AB provides pharmaceuticals against mental and physical symptoms. It develops antagonists to reduce symptoms and conditions caused by endogenous sex and stress hormones on the brain. The company was founded by Carl Torbjörn Bäckström in 2000 and is headquartered in Umea, Sweden. | Health Technology |
Galenica AB
Galenica AB Pharmaceuticals: MajorHealth Technology Galenica AB develops and manufactures pharmaceutical drugs. It offers service to partners for the development of oral, dermal, nasal, rectal, pulmonary and parenteral formulations of small molecules to peptides/proteins and biologics. The company was founded in 1999 and is headquartered in Malmo, Sweden. | Health Technology |
